AstraZeneca announces Results of AERISTO P-IIIb trial for Bevespi Aerosphere in COPD patients
AstraZeneca announces Results of AERISTO P-IIIb trial for Bevespi Aerosphere in COPD patients
Shots:
- The AERISTO study recruited 1,119 patients receiving either Bevespi Aerosphere (7.2/4.8µg) BID via pressurized metered-dose inhaler or umeclidinium/vilanterol (62.5/25µg) QD via dry powder inhaler
- Another P-III PINNACLE study enrolled ~5,000 patients and is performed to test safety and efficacy of Bevespi Aerosphere vs. umeclidinium/vilanterol
- Bevespi Aerosphere (glycopyrronium/formoterol fumarate) is approved in the US and Canada for COPD with an expected regulatory decision from EU by H2’18
Click here to read full press release/ article | Ref: AstraZeneca | Image: Forbes